Literature DB >> 2056199

Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine.

P Novotny1, A P Chubb, K Cownley, I G Charles.   

Abstract

A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (FHA), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test. A combination of the same 69-kDa protein and LPF is approximately 15 times less effective. These data suggest that, surprisingly, the 69-kDa protein in tandem with FHA is the most relevant combination for mouse protection; consequently such a combination may be a more suitable acellular pertussis vaccine candidate than the LPF/FHA combinations, which have never been satisfactorily protective in the mouse test. Preparation of samples of the 69-kDa protein of acceptable protective quality remains difficult. Attempts were made to screen the most suitable batches of the preparations by exploiting some recently discovered properties of the 69-kDa protein: the characteristic chromatofocusing pattern of the protein, the affinity for lymphocytes, and the ability to bind to nicotinamide adenine dinucleotide. None of these tests was able to replace the mouse intracerebral challenge potency test for final quality assessment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056199     DOI: 10.1093/infdis/164.1.114

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis.

Authors:  J W Gotto; T Eckhardt; P A Reilly; J V Scott; J L Cowell; T N Metcalf; K Mountzouros; J J Gibbons; M Siegel
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

2.  Pertactin is required for Bordetella species to resist neutrophil-mediated clearance.

Authors:  Carol S Inatsuka; Qian Xu; Ivan Vujkovic-Cvijin; Sandy Wong; Scott Stibitz; Jeff F Miller; Peggy A Cotter
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

3.  Reduced Bordetella pertussis-specific CD4+ T-Cell Responses at Older Age.

Authors:  Eleonora E Lambert; Inonge van Twillert; Lisa Beckers; Martien C M Poelen; Wanda G H Han; Daan K J Pieren; Cécile A C M van Els
Journal:  Front Aging       Date:  2022-02-02

4.  Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  R Shahin; M Leef; J Eldridge; M Hudson; R Gilley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

5.  Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid.

Authors:  C A Guzman; G Molinari; M W Fountain; M Rohde; K N Timmis; M J Walker
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

6.  Bordetella bronchiseptica-mediated cytotoxicity to macrophages is dependent on bvg-regulated factors, including pertactin.

Authors:  C B Forde; X Shi; J Li; M Roberts
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates.

Authors:  Jessica A Harris; Koushik Roy; Virginia Woo-Rasberry; David J Hamilton; Rita Kansal; Firdausi Qadri; James M Fleckenstein
Journal:  PLoS Negl Trop Dis       Date:  2011-12-06

8.  Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach.

Authors:  Isaac Amela; Juan Cedano; Enrique Querol
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.